RUNX1 and acute myeloid leukemia: Since some reports combined primary and secondary AML, Quesada et al. assessed the prognostic impact of RUNX1-mutated de novo AML according to the WHO definition and detected no differences in outcome [57], which is concordant with our findings in primary paediatric AML.